Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
461-480 of 653 trials

Hydroxychloroquine for Early Systemic Sclerosis

We are studying whether adding hydroxychloroquine to standard treatments helps improve symptoms in people with early systemic sclerosis. The trial will assess its safety and effectiveness compared to a placebo.

Systemic Sclerosis1-2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesInternal MedicineRheumatology

Retinitis Pigmentosa: GS030 Gene Therapy Study

We are evaluating a new gene therapy to see if it is safe and can improve vision in people with retinitis pigmentosa. Participants will receive a single injection and undergo light stimulation to assess potential benefits.

Retinitis Pigmentosa1-2 yearsSafety phase (I)Efficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOphthalmology

Polycystic Kidney Disease: GSK4771261 Study

We are evaluating a new medication for safety and effectiveness in healthy individuals and those with autosomal dominant polycystic kidney disease. This study aims to understand how the drug works in different groups of people.

Polycystic Kidney Disease (Autosomal Dominant)1-2 yearsSafety phase (I)Internal MedicineNephrology

Preventing Relapses in Minimal Change Nephrotic Syndrome with Rituximab

We are studying whether Rituximab can help adults with Minimal Change Nephrotic Syndrome stay in remission after their first episode. This trial looks at the effectiveness and safety of the treatment over time.

Minimal Change Nephrotic Syndrome1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesNephrology

Breast Cancer Treatment: Fulvestrant with Palbociclib

We are studying whether combining fulvestrant with palbociclib helps postmenopausal women with hormone receptor-positive metastatic breast cancer live longer without disease progression compared to fulvestrant alone. This trial is for women who have completed at least five years of hormonal therapy and remained disease-free for over a year, or who have newly diagnosed metastatic disease.

Metastatic Breast Cancer1-2 yearsEfficacy phase (II)Standard MedicinesOncology

Neuroendocrine Neoplasms: Advanced PET/CT Imaging Study

We are exploring how combined PET/CT scans can help predict survival outcomes for patients with neuroendocrine neoplasms. This study may also identify who is eligible for targeted therapies based on imaging results.

Neuroendocrine Carcinoma1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesEndocrinologyOncology

Metastatic Colorectal Cancer: S 95005 with Bevacizumab

We are studying a new treatment combination for patients with metastatic colorectal cancer who cannot receive intensive therapy. The goal is to see if it helps patients live longer without disease progression compared to standard treatment.

Metastatic Colorectal Cancer1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Psoriatic Arthritis: Sonelokimab Treatment Study

We are investigating whether sonelokimab can effectively reduce symptoms in adults with active psoriatic arthritis who have not yet tried biologic treatments. The study will also assess the safety of this new medication compared to a placebo.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatologyRheumatology

Psoriatic Arthritis: Sonelokimab Study

We are investigating the effects of sonelokimab in adults with active psoriatic arthritis who haven't responded to other treatments. This study compares sonelokimab to a placebo and an existing medication to see how well it works.

Psoriatic Arthritis1-2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementDermatologyRheumatology

Ulcerative Colitis: Vixarelimab Study

We are testing Vixarelimab to see if it is safe and effective for people with moderate to severe active ulcerative colitis. This study aims to improve treatment options for this condition.

Ulcerative Colitis1-2 yearsSafety phase (I)GastroenterologyInternal Medicine

Sjögren’s Disease: Sibeprenlimab Treatment Study

We are investigating whether Sibeprenlimab can improve symptoms in people with Sjögren’s Disease compared to a placebo. The study will also look at the safety and tolerability of this new treatment.

Sjögren's Disease1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInfectious DiseasesRheumatology

Lung Fibrosis in Systemic Rheumatic Diseases: Imaging Study

We are investigating whether advanced imaging can help identify early signs of lung fibrosis in patients with systemic rheumatic diseases. This may help us understand lung function changes and improve patient care.

Connective Tissue Disease with Risk of Lung Disease1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPulmonologyRheumatology

HER2 Positive Metastatic Breast Cancer: ES2B-C001 Study

We are assessing the safety of a new treatment called ES2B-C001, with or without Montanide, for patients with HER2 expressing metastatic breast cancer. This trial aims to understand how safe this new approach is for patients.

HER2 Positive Breast Cancer1-2 yearsSafety phase (I)Oncology

TAR-0520 Gel for Folliculitis in Colorectal Cancer Patients

We are testing a new gel to see if it is safe and effective for preventing skin irritation in patients using EGFR inhibitors for colorectal cancer. This study focuses on its use on the face and chest.

Papuloerythematous Drug EruptionEGFR Inhibitor-Induced Folliculitis1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementDermatologyOncology

Eculizumab for Hypertensive Emergency-Associated Kidney Condition

We are studying whether Eculizumab can improve kidney function in patients with a severe kidney condition linked to high blood pressure. This trial will help us understand its effects on dialysis needs and overall health.

Atypical Hemolytic Uremic Syndrome (aHUS)1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesInternal MedicineNephrology

Glycerol Phenylbutyrate for Pyruvate Dehydrogenase Deficiency

We are studying whether Glycerol Phenylbutyrate can help reduce fatigue and improve quality of life for patients with Pyruvate Dehydrogenase Deficiency. The trial will also assess its safety and effects on neurodevelopmental symptoms.

Pyruvate Dehydrogenase Deficiency1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyGastroenterologyNeurology

Urothelial Cancer: DDR Gene Testing for Chemotherapy Response

We are studying whether changes in DDR genes can help predict how well patients with advanced urothelial cancer respond to platinum-based chemotherapy. This may lead to better treatment decisions for patients based on their genetic profile.

Metastatic or Locally Advanced Urothelial Cancer1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOncologyUrology

Rheumatoid Arthritis: GS-0151 Treatment Study

We are investigating a new medication, GS-0151, for people with rheumatoid arthritis. The goal is to see how it may help manage symptoms and improve quality of life.

Rheumatoid Arthritis1-2 yearsSafety phase (I)Internal MedicineRheumatology

Type 2 Diabetes: Personalized Treatment Study

We are exploring how different diabetes medications work for patients based on their insulin response. The goal is to find biomarkers that help tailor treatments for better management of type 2 diabetes.

Type 2 Diabetes1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesEndocrinologyInternal Medicine

Bipolar Disorder: Low-Dose Aspirin Study

We are investigating whether adding low-dose aspirin to standard treatment helps improve symptoms in patients with bipolar disorder. This study aims to assess both the effectiveness and safety of this approach.

Bipolar Disorder1-2 yearsEfficacy phase (II)Standard MedicinesPartially RemotePsychiatry